Ran Frenkel has sold KPTI and made no open-market buys since Nov 2016
EVP, Chief Dev. Officer at Karyopharm Therapeutics Inc.
SEC CIK 0001623108 · Filings on SEC.gov ↗
$0Bought
$288KSold
NoneLast buy
Every filing
7 filings since Nov 2016, newest first
KPTISell
Karyopharm Therapeutics Inc.
EVP, Chief Dev. Officer
$36K−3.0%Feb 22
KPTISell
Karyopharm Therapeutics Inc.
EVP, Chief Dev. Officer
$43K−6.0%Feb 22
KPTISell
Karyopharm Therapeutics Inc.
EVP, Chief Dev. Officer
$32K−4.0%Feb 17
KPTISell
Karyopharm Therapeutics Inc.
Chief Dev Operations Officer
$39K−5.0%May 11
KPTISell
Karyopharm Therapeutics Inc.
Chief Dev Operations Officer
$49K−8.0%Feb 21
KPTISell
Karyopharm Therapeutics Inc.
Chief Dev Operations Officer
$56K−17.0%Nov 9
KPTISell
Karyopharm Therapeutics Inc.
Chief Dev Operations Officer
$33K−18.0%Nov 15
Filings come from SEC EDGAR. Not investment advice.